PET applications in animal models of neurodegenerative and neuroinflammatory disorders.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Current topics in behavioral neurosciences

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/7854_2011_167PMID 22016108
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical trials and drug development.

  2014cited by this paper
• Alzheimer's disease.

  2011cited by this paper
• In Vivo Positron Emission Tomographic Imaging of Glial Responses to Amyloid-β and Tau Pathologies in Mouse Models of Alzheimer's Disease and Related Disorders

  2011cited by this paper
• Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease.

  2011cited by this paper
• Simultaneous assessment of rodent behavior and neurochemistry using a miniature positron emission tomograph

  2011cited by this paper
• Physiology of microglia.

  2011cited by this paper
• 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease.

  2011influential reference
• In Vivo Expression of Cyclooxygenase-1 in Activated Microglia and Macrophages During Neuroinflammation Visualized by PET with 11C-Ketoprofen Methyl Ester

  2011cited by this paper
• Radiosynthesis of novel carbon-11-labeled triaryl ligands for cannabinoid-type 2 receptor.

  2010cited by this paper
• Medical treatment of Parkinson's disease: today and the future.

  2010cited by this paper
• Inflammation in neurodegenerative diseases

  2010cited by this paper
• Glial Cell–Mediated Deterioration and Repair of the Nervous System after Traumatic Brain Injury in a Rat Model as Assessed by Positron Emission Tomography

  2010cited by this paper
• Alzheimer's disease: clinical trials and drug development

  2010cited by this paper
• In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: a PET and MRI study.

  2010cited by this paper
• A Mouse Model of Amyloid β Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss In Vivo

  2010cited by this paper
• Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging.

  2010cited by this paper
• Pyroglutamate-Aβ: role in the natural history of Alzheimer's disease.

  2010cited by this paper
• Establishment of In Vivo Brain Imaging Method in Conscious Mice

  2010cited by this paper
• IC‐P‐007: Memory loss in young APPswe/PS1dE9 mice and associated changes in brain metabolism analyzed using a 3‐D voxel‐based approach

  2009cited by this paper
• Utility of small-animal positron emission tomographic imaging of rats for preclinical development of drugs acting on the serotonin transporter.

  2009cited by this paper
• Neuroprotective and toxic changes in microglia in neurodegenerative disease.

  2009cited by this paper
• Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies

  2009influential reference
• Neuroimaging and Physiological Evidence for Involvement of Glutamatergic Transmission in Regulation of the Striatal Dopaminergic System

  2009cited by this paper
• IC‐P‐009: In vivo optical and PET detections of fibrillar tau lesions in a mouse model of tauopathies

  2009cited by this paper
• Abeta-degrading enzymes in Alzheimer's disease.

  2008cited by this paper
• SYMPOSIUM: Clearance of Aβ from the Brain in Alzheimer's Disease: Aβ‐Degrading Enzymes in Alzheimer's Disease

  2008cited by this paper
• Quantification of 11C-PIB kinetics in mouse brain using metabolite-corrected arterial input function

  2008cited by this paper
• Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta.

  2008cited by this paper
• Imaging of Peripheral Benzodiazepine Receptor Expression as Biomarkers of Detrimental versus Beneficial Glial Responses in Mouse Models of Alzheimer's and Other CNS Pathologies

  2008cited by this paper
• Alpha-CaMKII deficiency causes immature dentate gyrus, a novel candidate endophenotype of psychiatric disorders

  2008cited by this paper
• Evaluation of [(11)C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation.

  2008cited by this paper
• Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106.

  2008cited by this paper
• Occupancy of dopamine D2/3 receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [11C]MNPA

  2008cited by this paper
• Microglia-mediated neurotoxicity: uncovering the molecular mechanisms

  2007cited by this paper
• The role of amyloid β peptide 42 in Alzheimer's disease

  2007cited by this paper
• Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model.

  2007influential reference
• Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography

  2007cited by this paper
• 11C-AC-5216: A Novel PET Ligand for Peripheral Benzodiazepine Receptors in the Primate Brain

  2007cited by this paper
• Imaging Brain Inflammation with [11C]PK11195 by PET and Induction of the Peripheral-Type Benzodiazepine Receptor after Transient Focal Ischemia in Rats

  2007cited by this paper
• Radioligand development for PET imaging of beta-amyloid (Abeta)--current status.

  2007cited by this paper
• Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor.

  2007cited by this paper
• Radioligand Development for PET Imaging of β-Amyloid (Aβ)-Current Status

  2007cited by this paper
• The role of amyloid beta peptide 42 in Alzheimer's disease.

  2007cited by this paper
• [11C]PIB in a nondemented population

  2006cited by this paper
• PET of brain amyloid and tau in mild cognitive impairment.

  2006cited by this paper
• The significance of neuroinflammation in understanding Alzheimer’s disease

  2006cited by this paper
• Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

  2006cited by this paper
• Neprilysin-sensitive Synapse-associated Amyloid-β Peptide Oligomers Impair Neuronal Plasticity and Cognitive Function*

  2006cited by this paper
• On the seeding and oligomerization of pGlu-amyloid peptides (in vitro).

  2006cited by this paper
• Mass effect of injected dose in small rodent imaging by SPECT and PET.

  2005cited by this paper
• PET imaging of brain with the β-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer’s disease

  2005cited by this paper
• APP23 Mice as a Model of Alzheimer's Disease: An Example of a Transgenic Approach to Modeling a CNS Disorder

  2005cited by this paper
• Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B

  2005cited by this paper
• Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-β in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain

  2005influential reference
• Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.

  2005influential reference
• Inhibition of Heparin-induced Tau Filament Formation by Phenothiazines, Polyphenols, and Porphyrins*

  2005cited by this paper
• Microglial activation and dopamine terminal loss in early Parkinson's disease

  2005cited by this paper
• Infectious disease: Unravelling SARS lethality

  2005cited by this paper
• Quinoline and Benzimidazole Derivatives: Candidate Probes for In Vivo Imaging of Tau Pathology in Alzheimer's Disease

  2005cited by this paper
• Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging.

  2005cited by this paper
• Peripheral benzodiazepine receptor imaging in CNS demyelination: functional implications of anatomical and cellular localization.

  2004cited by this paper
• Absolute quantification of regional cerebral glucose utilization in mice by 18F-FDG small animal PET scanning and 2-14C-DG autoradiography.

  2004cited by this paper
• Novel peripheral benzodiazepine receptor ligand [11C]DAA1106 for PET: An imaging tool for glial cells in the brain

  2004cited by this paper
• Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

  2004cited by this paper
• Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs

  2004cited by this paper
• Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-β structure

  2003cited by this paper
• The endophenotype concept in psychiatry: etymology and strategic intentions.

  2003cited by this paper
• Pyroglutamate‐modified amyloid β‐peptides – AβN3(pE) – strongly affect cultured neuron and astrocyte survival

  2002cited by this paper
• Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration.

  2002cited by this paper
• Pyroglutamate-modified amyloid beta-peptides--AbetaN3(pE)--strongly affect cultured neuron and astrocyte survival.

  2002cited by this paper
• Tau and axonopathy in neurodegenerative disorders

  2002cited by this paper
• Functional Brain Mapping of Monkey Tool Use

  2001cited by this paper
• Age-Dependent Changes in Brain , CSF , and Plasma Amyloid b Protein in the Tg 2576 Transgenic Mouse Model of Alzheimer ’ s Disease

  2001cited by this paper
• Imaging neurochemical endophenotypes: promises and pitfalls.

  2001cited by this paper
• In-vivo measurement of activated microglia in dementia.

  2001influential reference
• Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease

  2001cited by this paper
• Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition

  2000cited by this paper
• Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review

  2000cited by this paper
• Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein

  2000cited by this paper
• Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein

  2000cited by this paper
• Reply to: 'Clearance of amyloid β-peptide from brain: transport or metabolism?'

  2000cited by this paper
• The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity.

  2000cited by this paper
• The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta.

  1999cited by this paper
• Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease

  1999cited by this paper
• The Aβ 3-Pyroglutamyl and 11-Pyroglutamyl Peptides Found in Senile Plaque Have Greater β-Sheet Forming and Aggregation Propensities in Vitro than Full-Length Aβ†

  1999cited by this paper
• Astrocytes Couple Synaptic Activity to Glucose Utilization in the Brain.

  1999cited by this paper
• Tau is a candidate gene for chromosome 17 frontotemporal dementia

  1998cited by this paper
• Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals

  1998cited by this paper
• Mutation in the tau gene in familial multiple system tauopathy with presenile dementia.

  1998influential reference
• Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes

  1998cited by this paper
• Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17

  1998cited by this paper
• Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology.

  1997cited by this paper
• Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice

  1996cited by this paper
• The contribution of astrocytes to the 18F-2-deoxyglucose signal in PET activation studies.

  1996cited by this paper
• Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

  1995cited by this paper
• Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene

  1995cited by this paper
• Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques.

  1995cited by this paper
• Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene

  1991cited by this paper

• Experimental basis for generating nonhuman primate models of frontotemporal dementia and Alzheimer's disease

  2025cites this paper
• Preclinical and Clinical Aspects of Nicotinic Acetylcholine Receptor Imaging

  2020cites this paper
• Quantitative imaging of protein targets in the human brain with PET

  2015cites this paper
• Preclinical Aspects of Nicotinic Acetylcholine Receptor Imaging

  2014cites this paper